Short Interest in Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Decreases By 57.8%

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the target of a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling 192,649 shares, a decrease of 57.8% from the January 15th total of 456,520 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Jefferies Financial Group initiated coverage on Hansa Biopharma AB (publ) in a research report on Wednesday, October 29th. They issued a “buy” rating for the company. Wedbush initiated coverage on shares of Hansa Biopharma AB (publ) in a research note on Wednesday, January 7th. They set an “outperform” rating for the company. Finally, HC Wainwright restated a “buy” rating on shares of Hansa Biopharma AB (publ) in a report on Thursday. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Hansa Biopharma AB (publ) Price Performance

Shares of HNSBF stock remained flat at $2.91 on Friday. The stock’s 50-day moving average price is $2.91 and its 200-day moving average price is $3.18. Hansa Biopharma AB has a fifty-two week low of $2.73 and a fifty-two week high of $4.58.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.